TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Decision Making: Ein Kommunikationstraining für Patienten Mit Schizophrenie
Brief Summary: Patients suffering from schizophrenia who attend the communication skills program engage more deeply in therapeutic reasoning and treatment decisions. This results in stronger preferences to participate, greater perceived involvement and better long term adherence compared to patients who do not attend the training.


Options:
A: Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard | Arm Label: Decision Support & Navigation; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support & Navigation | Intervention Type: BEHAVIORAL; Name: Decision Support & Navigation; Assigned to Arm(s): Decision Support & Navigation | Intervention Type: BEHAVIORAL; Name: Standard; Assigned to Arm(s): Standard
B: Arm Label: Personalized Web Intervention Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Personalized Web Intervention Arm | Arm Label: Usual Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Arm | Intervention Type: BEHAVIORAL; Name: Usual Care Arm; Assigned to Arm(s): Usual Care Arm | Intervention Type: BEHAVIORAL; Name: Personalized Web Intervention Arm; Assigned to Arm(s): Personalized Web Intervention Arm
C: Arm Label: communication skills training; Type: EXPERIMENTAL; Interventions: Behavioral: patient training in shared decision making | Arm Label: cognitive training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive training | Intervention Type: BEHAVIORAL; Name: patient training in shared decision making; Assigned to Arm(s): communication skills training | Intervention Type: BEHAVIORAL; Name: cognitive training; Assigned to Arm(s): cognitive training
D: Arm Label: Active Implementation phase; Type: OTHER; Interventions: Other: Uterine Fibroid Option Grid encounter patient decision aid (text only), Other: Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures), Other: Uterine Fibroid Option Grid encounter patient decision aid (online) | Intervention Type: OTHER; Name: Uterine Fibroid Option Grid encounter patient decision aid (text only); Assigned to Arm(s): Active Implementation phase | Intervention Type: OTHER; Name: Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures); Assigned to Arm(s): Active Implementation phase | Intervention Type: OTHER; Name: Uterine Fibroid Option Grid encounter patient decision aid (online); Assigned to Arm(s): Active Implementation phase

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Decision Making: Ein Kommunikationstraining für Patienten Mit Schizophrenie
Brief Summary: Patients suffering from schizophrenia who attend the communication skills program engage more deeply in therapeutic reasoning and treatment decisions. This results in stronger preferences to participate, greater perceived involvement and better long term adherence compared to patients who do not attend the training.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Other: Australian Government Bowel Cancer Screening booklet | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Australian Government Bowel Cancer Screening booklet; Assigned to Arm(s): 3
B: Arm Label: communication skills training; Type: EXPERIMENTAL; Interventions: Behavioral: patient training in shared decision making | Arm Label: cognitive training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: cognitive training | Intervention Type: BEHAVIORAL; Name: patient training in shared decision making; Assigned to Arm(s): communication skills training | Intervention Type: BEHAVIORAL; Name: cognitive training; Assigned to Arm(s): cognitive training
C: Arm Label: PCI Choice decision; Type: ACTIVE_COMPARATOR; Interventions: Other: Decision Aid | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): PCI Choice decision
D: Arm Label: Framingham Risk Score; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Framingham and Genetic Risk Score; Type: ACTIVE_COMPARATOR; Interventions: Other: Genetic Risk Score | Intervention Type: OTHER; Name: Genetic Risk Score; Assigned to Arm(s): Framingham and Genetic Risk Score

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Partnership for the Rapid Elimination of Trachoma (PRET) Clinical Trial of Evaluation of Modified Instrumentation for Surgery to Correct Trichiasis
Brief Summary: Trachoma, an ocular infection caused by C. trachomatis, is the second leading infectious cause of blindness worldwide. Years of repeated infection with C. trachomatis cause the eyelid to scar and contract and ultimately to rotate inward such that the eyelashes rub against the eyeball and abrade the cornea (trichiasis). The World Health Organization (WHO) has endorsed a multi-faceted strategy to combat trachoma which includes surgery to repair lids distorted by trachoma (trichiasis) in imminent danger of vision loss. Current evidence suggests that long-term success rates of trichiasis surgery are less than optimal due to variation in surgical technique. Previous research by this study team has demonstrated that shorter incisions have a higher rate of trichiasis recurrence. In addition, observations by this team's oculoplastic surgeon have led to the hypothesis that granuloma formation and lid contour abnormalities may result from current surgical practices. The objective of this study is to compare outcomes of trichiasis surgeries performed with the newly developed trachomatous trichiasis (TT) clamp versus surgeries following standard technique (bilamellar tarsal rotation procedure or BLTR).


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: topical tetracycline | Arm Label: Intervention 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin | Arm Label: Intervention 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): Intervention 1, Intervention 2 | Intervention Type: DRUG; Name: topical tetracycline; Assigned to Arm(s): Control
B: Arm Label: Vicryl Suture; Type: EXPERIMENTAL; Interventions: Procedure: Trichiasis surgery with absorbable sutures | Arm Label: Silk Suture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trichiasis surgery with non-absorbable sutures | Intervention Type: PROCEDURE; Name: Trichiasis surgery with absorbable sutures; Assigned to Arm(s): Vicryl Suture | Intervention Type: PROCEDURE; Name: Trichiasis surgery with non-absorbable sutures; Assigned to Arm(s): Silk Suture
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Trichiasis surgery | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Epilation | Intervention Type: PROCEDURE; Name: Trichiasis surgery; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Epilation; Assigned to Arm(s): B
D: Arm Label: TT Clamp; Type: EXPERIMENTAL; Interventions: Device: TT Clamp | Arm Label: Standard BLTR Technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard BLTR Technique | Intervention Type: DEVICE; Name: TT Clamp; Assigned to Arm(s): TT Clamp | Intervention Type: PROCEDURE; Name: Standard BLTR Technique; Assigned to Arm(s): Standard BLTR Technique

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomised Multicentre Comparison on Health Related Quality of Life: the Value of Add-on Arrhythmia Surgery in Patients With Atrial Fibrillation Undergoing Valvular and/or Coronary Bypass Surgery
Brief Summary: Atrial fibrillation (AF) is connected with an increased morbidity and mortality. In addition, quality of life is diminished due to palpitations, dyspnea, dizziness and syncope. AF is frequently associated with valvular and coronary disease. In the AF patients undergoing valvular or coronary surgery the arrhythmia almost always relapses. For symptom control anti-arrhythmic drugs and cardioversion are used but breakthrough arrhythmias and side effects of the drugs happen frequently. For more effective symptom control "add-on" arrhythmia surgery is being advocated. However, at present the investigators do not know whether add-on arrhythmia surgery indeed affects morbidity and quality of life.

The hypothesis being studied is that add-on arrhythmia surgery in patients with AF undergoing valvular or coronary surgery improves quality of life, establishes chronic sinus rhythm and reduces perioperative and long-term morbidity associated with AF.


Options:
A: Arm Label: Add-on arrhythmia surgery; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary vein isolation using microwave energy | Intervention Type: PROCEDURE; Name: Pulmonary vein isolation using microwave energy; Assigned to Arm(s): Add-on arrhythmia surgery
B: Arm Label: left atrial RF ablation groups; Type: EXPERIMENTAL; Interventions: Procedure: Cardioblate® Surgical Ablation System | Arm Label: Bi-atrial radiofrequency ablation group; Type: EXPERIMENTAL; Interventions: Procedure: Cardioblate® Surgical Ablation System | Arm Label: Amiodarone group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Cardioblate® Surgical Ablation System; Assigned to Arm(s): Bi-atrial radiofrequency ablation group, left atrial RF ablation groups
C: Intervention Type: DEVICE; Name: Radiofrequency ablation; Assigned to Arm(s): N/A
D: Arm Label: LAA Clip; Type: EXPERIMENTAL; Interventions: Device: AtriCure LAA Exclusion System | Intervention Type: DEVICE; Name: AtriCure LAA Exclusion System; Assigned to Arm(s): LAA Clip

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children: A Randomized, Controlled, Pilot Study
Brief Summary: The prevalence of severely obese children is on the rise. Behavioral therapies for weight loss are successful in some, but others need more aggressive approaches such as drug therapy. In addition, up to 25% of severely obese children have impaired glucose tolerance (IGT), which places them at significantly elevated risk of developing type 2 diabetes mellitus and cardiovascular disease. Although various drug therapies for weight loss and IGT have been explored in adults, few have been evaluated in children.

Recently, a new drug class has emerged that targets deficiencies of GLP-1. One of the main glycemic mechanisms of action of the GLP-1 agonists such as exenatide is to enhance glucose disposal in the postprandial setting and improve glucose tolerance. In addition, exenatide can induce weight loss by decreasing appetite and slowing gastric motility.


Options:
A: Arm Label: Litramine; Type: EXPERIMENTAL; Interventions: Device: Litramine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo | Intervention Type: DEVICE; Name: Litramine; Assigned to Arm(s): Litramine | Intervention Type: DEVICE; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide
C: Intervention Type: DRUG; Name: sibutramine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: glucophage XR; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Control Trial of Misoprostol vs. Placebo Prior to IUD Insertion in Nulliparous Women
Brief Summary: The purpose of this study is to see if inserting misoprostol in the vagina or between your cheek and gum before inserting an Intrauterine Device (IUD) in a woman who has never had a baby makes it easier and less painful.


Options:
A: Arm Label: intracervical anesthesia; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intracervical anesthesia with lidocaine 2% | Arm Label: ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: ibuprofen 400 mg | Intervention Type: DRUG; Name: Intracervical anesthesia with lidocaine 2%; Assigned to Arm(s): intracervical anesthesia | Intervention Type: DRUG; Name: ibuprofen 400 mg; Assigned to Arm(s): ibuprofen
B: Arm Label: misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Immediate IUD insertion | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Immediate IUD insertion; Assigned to Arm(s): 1
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol
Brief Summary: The purpose of this study is to compare the efficacy for cervical ripening in labor induction between titrated and conventional oral misoprostol


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): 2
B: Arm Label: conventional oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Arm Label: titrated oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): conventional oral misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): titrated oral misoprostol
C: Arm Label: Oral Titrated Misoprostol Solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Vaginal Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Oral Titrated Misoprostol Solution | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Vaginal Misoprostol
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol
Brief Summary: The purpose of this study is to compare the efficacy for cervical ripening in labor induction between titrated and conventional oral misoprostol


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1, 2
B: Arm Label: Oxytocin augmentation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Misoprostol augmentation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol augmentation | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin augmentation
C: Arm Label: conventional oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Arm Label: titrated oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): conventional oral misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): titrated oral misoprostol
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol
Brief Summary: The purpose of this study is to compare the efficacy for cervical ripening in labor induction between titrated and conventional oral misoprostol


Options:
A: Arm Label: conventional oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Arm Label: titrated oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): conventional oral misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): titrated oral misoprostol
B: Arm Label: Oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Vaginal misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Oral misoprostol, Vaginal misoprostol
C: Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: dinoprostone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dinoprostone | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: DRUG; Name: Dinoprostone; Assigned to Arm(s): dinoprostone
D: Arm Label: misoprostol/placebo using buccal; Type: PLACEBO_COMPARATOR; Interventions: Drug: misoprostol/placebo | Arm Label: misoprostol/placebo using vaginal; Type: PLACEBO_COMPARATOR; Interventions: Drug: misoprostol/placebo | Intervention Type: DRUG; Name: misoprostol/placebo; Assigned to Arm(s): misoprostol/placebo using buccal, misoprostol/placebo using vaginal

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Brief Summary: This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC).


Options:
A: Arm Label: Mitoxantrone + Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: mitoxantrone, Drug: prednisone | Arm Label: Cabazitaxel + Prednisone; Type: EXPERIMENTAL; Interventions: Drug: cabazitaxel (XRP6258) (RPR116258), Drug: prednisone | Intervention Type: DRUG; Name: cabazitaxel (XRP6258) (RPR116258); Assigned to Arm(s): Cabazitaxel + Prednisone | Intervention Type: DRUG; Name: mitoxantrone; Assigned to Arm(s): Mitoxantrone + Prednisone | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Cabazitaxel + Prednisone, Mitoxantrone + Prednisone
B: Arm Label: Placebo + prednisone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Prednisone | Arm Label: Abiraterone + prednisone; Type: EXPERIMENTAL; Interventions: Drug: Abiraterone acetate, Drug: Prednisone | Intervention Type: DRUG; Name: Abiraterone acetate; Assigned to Arm(s): Abiraterone + prednisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Abiraterone + prednisone, Placebo + prednisone
C: Arm Label: APC-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: APC-Placebo | Arm Label: Sipuleucel-T; Type: ACTIVE_COMPARATOR; Interventions: Biological: Sipuleucel-T | Intervention Type: BIOLOGICAL; Name: Sipuleucel-T; Assigned to Arm(s): Sipuleucel-T | Intervention Type: BIOLOGICAL; Name: APC-Placebo; Assigned to Arm(s): APC-Placebo
D: Arm Label: Enzalutamide; Type: EXPERIMENTAL; Interventions: Drug: Enzalutamide, Drug: LHRHA or Surgical Castration | Arm Label: Conventional NSAA; Type: ACTIVE_COMPARATOR; Interventions: Drug: NSAA, Drug: LHRHA or Surgical Castration | Intervention Type: DRUG; Name: Enzalutamide; Assigned to Arm(s): Enzalutamide | Intervention Type: DRUG; Name: NSAA; Assigned to Arm(s): Conventional NSAA | Intervention Type: DRUG; Name: LHRHA or Surgical Castration; Assigned to Arm(s): Conventional NSAA, Enzalutamide

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extending the Time for Thrombolysis in Emergency Neurological Deficits
Brief Summary: The primary hypothesis being tested in this trial is that ischaemic stroke patients selected with significant penumbral mismatch (measured by MRI criteria) at 3 - 9 hours post onset of stroke will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to placebo.


Options:
A: Arm Label: IV tPA; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): IV tPA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
D: Arm Label: Desmoteplase, low dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Desmoteplase, high dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, low dose | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A